SG Americas Securities LLC lowered its stake in shares of Celgene Co. (NASDAQ:CELG) by 58.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,558 shares of the biopharmaceutical company’s stock after selling 84,002 shares during the quarter. SG Americas Securities LLC’s holdings in Celgene were worth $6,013,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in the business. Thomasville National Bank lifted its position in Celgene by 1.1% during the second quarter. Thomasville National Bank now owns 32,802 shares of the biopharmaceutical company’s stock valued at $3,032,000 after purchasing an additional 365 shares during the last quarter. Syquant Capital Sas bought a new position in Celgene during the second quarter valued at $35,118,000. WINTON GROUP Ltd lifted its position in Celgene by 50.1% during the second quarter. WINTON GROUP Ltd now owns 196,768 shares of the biopharmaceutical company’s stock valued at $18,189,000 after purchasing an additional 65,656 shares during the last quarter. Calton & Associates Inc. lifted its position in Celgene by 9.5% during the second quarter. Calton & Associates Inc. now owns 5,277 shares of the biopharmaceutical company’s stock valued at $488,000 after purchasing an additional 456 shares during the last quarter. Finally, Contravisory Investment Management Inc. bought a new position in Celgene during the second quarter valued at $62,000. 72.31% of the stock is currently owned by institutional investors.
CELG has been the subject of several research reports. Standpoint Research lowered shares of Celgene from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Mizuho reissued a “hold” rating and issued a $100.00 target price on shares of Celgene in a research note on Sunday, October 20th. ValuEngine downgraded shares of Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. BidaskClub raised shares of Celgene from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Leerink Swann set a $115.00 target price on shares of Celgene and gave the company a “hold” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, nineteen have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. Celgene currently has a consensus rating of “Hold” and a consensus target price of $97.31.
CELG stock traded up $0.54 during trading on Friday, hitting $109.54. The company had a trading volume of 5,706,800 shares, compared to its average volume of 6,764,924. Celgene Co. has a 52-week low of $58.59 and a 52-week high of $109.75. The firm has a market capitalization of $76.64 billion, a P/E ratio of 14.39, a PEG ratio of 0.51 and a beta of 1.41. The company has a quick ratio of 2.80, a current ratio of 2.89 and a debt-to-equity ratio of 1.51. The company has a 50 day simple moving average of $102.54 and a 200-day simple moving average of $96.76.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $2.99 earnings per share for the quarter, beating analysts’ consensus estimates of $2.70 by $0.29. The business had revenue of $4.52 billion for the quarter, compared to analysts’ expectations of $4.39 billion. Celgene had a net margin of 34.63% and a return on equity of 78.15%. The company’s revenue was up 16.1% compared to the same quarter last year. During the same period last year, the business earned $2.29 EPS. Sell-side analysts forecast that Celgene Co. will post 10.7 earnings per share for the current year.
In related news, insider Terrie Curran sold 11,338 shares of Celgene stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $98.27, for a total value of $1,114,185.26. Following the completion of the sale, the insider now directly owns 13,493 shares in the company, valued at approximately $1,325,957.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.39% of the stock is owned by company insiders.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
See Also: Is it Safe to Invest in Commodities?
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.